MUC1 and prostate carcinoma: However, due to heterogeneous and fluctuated expression of the Muc1 antigen on prostate cancer cells, the immunotherapy could also induce the outgrowth of target-antigen loss variant or emergence of a new tumor phenotype, thereby leading to immune escape134.